Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Tivic Health Systems ( (TIVC) ).
On December 9, 2025, Tivic Health Systems acquired the manufacturing and development assets of Scorpius Holdings, launching a new subsidiary, Velocity Bioworks, to provide contract development and manufacturing services. This acquisition allows Tivic to bring manufacturing in-house, reducing costs and accelerating the development of its lead drug, Entolimod, while also creating new revenue opportunities by serving other biotech companies. The acquisition was financed by a $16 million debt and up to $75 million in preferred convertible equity led by 3i, LP. Additionally, Tivic terminated its Equity Purchase Agreement with Mast Hill Fund, L.P. on December 9, 2025.
Spark’s Take on TIVC Stock
According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.
The overall stock score of 43 reflects Tivic Health Systems’ current financial difficulties, including declining revenues and negative profitability. However, recent strategic initiatives and corporate events provide some optimism for future growth. The stock’s technical indicators and valuation remain weak, necessitating significant improvements in financial performance and market sentiment to enhance stock attractiveness.
To see Spark’s full report on TIVC stock, click here.
More about Tivic Health Systems
Tivic Health Systems, Inc. is a diversified therapeutics company focused on harnessing the immune system to improve clinical outcomes. The company specializes in biologics compounds that activate innate immune pathways to prevent cell death in bone marrow and epithelial tissues. Tivic’s lead drug candidate, Entolimod, is a TLR5 agonist for acute radiation syndrome, currently in late-stage development, and has been granted Fast Track and Orphan Drug designations. Tivic also holds rights to Entolimod for neutropenia treatment and Entolasta for chronic applications.
Average Trading Volume: 77,121
Technical Sentiment Signal: Sell
Current Market Cap: $4.11M
See more insights into TIVC stock on TipRanks’ Stock Analysis page.